# Actovegin 12-Week Treatment Given First Intravenously and Subsequently Orally in Participants With Peripheral Arterial Occlusive Disease Fontaine Stage IIB

Study · id `cardio:ct-nct03469349` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03469349](<https://clinicaltrials.gov/study/NCT03469349>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03469349

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 366 participants.

## Technical summary

Registry record NCT03469349. Randomized; double masking; primary purpose treatment. Start 2018-05-01 (actual); primary completion 2019-05-28 (actual). Results posted on 2020-10-28.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 366 participants (enrolled count; ClinicalTrials.gov record NCT03469349, source copy `cardio:ctgov-nct03469349-2020-10-28`, retrieved 2026-10-31)
- Started: 2018-05-01 (actual) (ClinicalTrials.gov record NCT03469349, source copy `cardio:ctgov-nct03469349-2020-10-28`, retrieved 2026-10-31)
- Primary completion: 2019-05-28 (actual) (ClinicalTrials.gov record NCT03469349, source copy `cardio:ctgov-nct03469349-2020-10-28`, retrieved 2026-10-31)
- Completion: 2019-08-28 (actual) (ClinicalTrials.gov record NCT03469349, source copy `cardio:ctgov-nct03469349-2020-10-28`, retrieved 2026-10-31)
- Results first posted: 2020-10-28 (ClinicalTrials.gov record NCT03469349, source copy `cardio:ctgov-nct03469349-2020-10-28`, retrieved 2026-10-31)
- Countries: Georgia; Kazakhstan; Russia (ClinicalTrials.gov record NCT03469349, source copy `cardio:ctgov-nct03469349-2020-10-28`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03469349-2020-10-28`, retrieved 2026-10-31)

## The registry's words

- Brief title: Actovegin 12-Week Treatment Given First Intravenously and Subsequently Orally in Participants With Peripheral Arterial Occlusive Disease Fontaine Stage IIB
- Acronym: APOLLO
- Condition: Peripheral Arterial Diseases
- Intervention (Drug): Actovegin
- Intervention (Drug): Placebo
- Lead sponsor: Takeda
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Peripheral artery disease (`cardio:peripheral-artery-disease`)
- Registry lists this organization as the lead sponsor: Takeda (`cardio:org-takeda`)

## Provenance

Content hash: 5e9e3a425b4eda5357935ee0c584d8d37bdf5e2e8abdad2215f54bdbc2e76039
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
